FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases

  • Erelzi is approved for all indications included in the reference product’s label
     
  • Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
     
  • Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars

Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …

/by

FDA approves Sandoz Erelzi™ to treat multiple inflammatory diseases

  • Erelzi is approved for all indications included in the reference product’s label
     
  • Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
     
  • Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars

Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …

/by